AssetMark Inc’s Enanta Pharmaceuticals ENTA Stock Holding History

AssetMark Inc’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5	Closed	–	–	1572
2017 Q4	$0	Buy	+5	New	+$250	﹤0.01%	1936
2017 Q1	–	Sell	-13	Closed	–	–	1310
2016 Q4	$0	Buy	+13	New	+$373	﹤0.01%	1278

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AssetMark Inc's ENTA Position: Q1 2018 in Review

AssetMark Inc sold out of Enanta Pharmaceuticals (ENTA) in Q1 2018, closing a stake of 5 shares.

AssetMark Inc first reported a position in ENTA in Q4 2016 and held it in 2 quarters. The position peaked at $0 in Q4 2017. 181 funds tracked by Wall St. Rank hold ENTA as of Q1 2018.

AssetMark Inc reported no remaining Enanta Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
AssetMark Inc sold 5 Enanta Pharmaceuticals shares in Q1 2018.
AssetMark Inc first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 2 quarters.
AssetMark Inc's Enanta Pharmaceuticals position peaked at $0 in Q4 2017.
181 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2018.

Based on AssetMark Inc's 13F filing for Q1 2018, filed 16 May 2018.